Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Larson3, Dong-Wook Kim4, Gabriel Etienne5, Gianantonio Rosti6, Carmino De Souza7, Mineo Kurokawa8, Matt E. Kalaycio9, Albert Hoenekopp10, Xiaolin Fan11, Yaping Shou11, Hagop M. Kantarjian12, and Timothy P. Hughes13

Key points:
~ Frontline nilotinib led to fewer and less diverse BCR-ABL mutations than imatinib in patients with chronic myeloid leukemia in chronic phase
~ Rates of progression to accelerated phase/blast crisis were lower with nilotinib than imatinib in patients with emergent BCR-ABL mutations

http://bloodjournal.hematologylibrary.org/content/early/2013/03/15/blood...